PMID- 27525671
OWN - NLM
STAT- MEDLINE
DCOM- 20170103
LR  - 20220408
IS  - 1085-5629 (Print)
IS  - 1085-5629 (Linking)
VI  - 35
IP  - 5 Suppl
DP  - 2016 Jun
TI  - Assessing the New and Emerging Treatments for Atopic Dermatitis.
PG  - S92-6
LID - 10.12788/j.sder.2016.043 [doi]
AB  - The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of 
      inflammatory cytokines, especially those that derive from T helper cell type 2 
      (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. 
      Among the proinflammatory cytokines that have been identified as promising 
      therapeutic targets are chemoattractant receptor-homologous molecule expressed on 
      TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several 
      monoclonal antibodies that block key cytokine pathways in the innate immune 
      response. Two agents that have been studied in phase III clinical trials are the 
      boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an 
      antibody that inhibits the interleukin-4/ IL-13 receptor alpha chain. Semin Cutan Med 
      Surg 35(supp5):S92-S96.
CI  - 2016 published by Frontline Medical Communications.
FAU - Eichenfield, Lawrence F Md
AU  - Eichenfield LF Md
AD  - Professor of Dermatology and Pediatrics Chief, Pediatric and Adolescent 
      Dermatology University of California San Diego School of Medicine Rady Children's 
      Hospital San Diego, California.
FAU - Friedlander, Sheila F Md
AU  - Friedlander SF Md
AD  - Professor of Dermatology and Pediatrics University of California San Diego School 
      of Medicine Fellowship Program Director Pediatric and Adolescent Dermatology Rady 
      Children's Hospital San Diego, California.
FAU - Simpson, Eric L Md McR
AU  - Simpson EL Md McR
AD  - Professor of Dermatology Director of Clinical Studies Oregon Health and Science 
      University Department of Dermatology Portland, Oregon.
FAU - Irvine, Alan D Md
AU  - Irvine AD Md
AD  - Professor of Dermatology Trinity College Dublin Attending Dermatologist Our 
      Lady's Children's Hospital Crumlin St. James's Hospital Dublin, Ireland.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Semin Cutan Med Surg
JT  - Seminars in cutaneous medicine and surgery
JID - 9617260
RN  - 0 (CRLF2 protein, human)
RN  - 0 (Interleukin-4 Receptor alpha Subunit)
RN  - 0 (Interleukins)
RN  - 0 (Phosphodiesterase 4 Inhibitors)
RN  - 0 (Receptors, Cytokine)
RN  - 1406-16-2 (Vitamin D)
RN  - EC 2.7.10.2 (Janus Kinases)
RN  - JL5DK93RCL (Melatonin)
SB  - IM
MH  - Child
MH  - Dermatitis, Atopic/complications/*drug therapy/prevention & control
MH  - Dietary Supplements
MH  - Humans
MH  - Interleukin-4 Receptor alpha Subunit/antagonists & inhibitors
MH  - Interleukins/antagonists & inhibitors
MH  - Janus Kinases/antagonists & inhibitors
MH  - Melatonin/therapeutic use
MH  - Phosphodiesterase 4 Inhibitors/therapeutic use
MH  - Receptors, Cytokine/antagonists & inhibitors
MH  - Vitamin D/therapeutic use
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - crisaborole
OT  - dupilumab
OT  - interleukin inhibitors
OT  - petrolatum
OT  - skin barrier
EDAT- 2016/08/16 06:00
MHDA- 2017/01/04 06:00
CRDT- 2016/08/16 06:00
PHST- 2016/06/01 00:00 [received]
PHST- 2016/06/31 00:00 [accepted]
PHST- 2016/08/16 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/01/04 06:00 [medline]
AID - 10.12788/j.sder.2016.043 [doi]
PST - ppublish
SO  - Semin Cutan Med Surg. 2016 Jun;35(5 Suppl):S92-6. doi: 10.12788/j.sder.2016.043.